Sugi Predict

Sugi Predict / Compounds / SCHEMBL1009338

SCHEMBL1009338

SCHEMBL1009338

O=C(O)C(CC1CCCC1)n1ncc(Oc2cccc3cnccc23)cc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR2F2 P24468 2/20 0.39
▸ GALR3 O60755 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SUCNR1 Q9BXA5 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ GRIN1 Q05586 2/20 0.37
▸ GRIN2B Q13224 2/20 0.37
▸ KCNA3 P22001 1/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ KDM4A O75164 1/20 0.35
▸ KDM5C P41229 1/20 0.35
▸ KDM4D Q6B0I6 1/20 0.35
▸ KDM4C Q9H3R0 1/20 0.35
▸ GPR132 Q9UNW8 1/20 0.35
▸ GPBAR1 Q8TDU6 1/20 0.35
▸ NR3C1 P04150 1/20 0.35
▸ SIRT2 Q8IXJ6 1/20 0.35
▸ SIRT1 Q96EB6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008568 0.91 SIRT2 (0.41) RAB9AKMT2AKDM4EGPBAR1SIRT2
SCHEMBL1008789 0.85 KCNH2 (0.40) RAB9ANPC1KMT2AKDM4EGPR132
SCHEMBL1008676 0.84 GPBAR1 (0.39) KMT2APDGFRBGPR132GPBAR1HCRTR1
SCHEMBL1008584 0.82 HIF1A (0.36) KMT2AKDM4EKDM4CGPBAR1
SCHEMBL1058556 0.82 GPBAR1 (0.38) PDGFRBGPBAR1
SCHEMBL1007742 0.82 GPR132 (0.42) RAB9AKMT2AKDM4EGPR132
SCHEMBL1008126 0.81 EGLN1 (0.42) GRIN1GRIN2BGPBAR1
SCHEMBL1008265 0.81 FFAR1 (0.40) KMT2AKDM4E
SCHEMBL1008741 0.81 LPAR1 (0.39) KMT2AHCRTR1HCRTR2
SCHEMBL1007288 0.81 LPAR1 (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK NR2F2 1310/4885GALR3 1900/4885RAB9A 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.